Increased vascular density with indirect myocardial revascularization in normal rat hearts
Main Article Content
Keywords
Cardiac surgical procedures, Myocardial revascularization, Blood proteins
Abstract
Background: The aim of this study was to identify if the interaction of myocardial revascularization methods increases the functional vascular area.
Methods: A 4x3 factorial design was performed in 11 groups, five rats per group, ten samples per rat, evaluated at 45 days postoperative, with different surgical combinations. The magnitude of the interaction was evaluated by immunoexpression of vascular endothelium-derived growth factor, fibroblast growth factor and tyrosine receptor, to allow the activity of vascular endothelium-derived growth factor, fibroblast growth factor and thrombin (Flk-1), as well as vascular area measurement; Both measures were performed by computerized morphometry.
Results: An increase in immunohistochemical expression and vascular area in direct proportion to the interaction was identified; It can be affirmed (ANOVA p < 0.0001), that with the interaction of all the maneuvers the maximum effect is achieved.
Conclusions: It is demonstrated that indirect myocardial revascularization has a specific weight within the integral myocardial revascularization with a real impact on cost-benefit and cost-effectiveness.
References
Serrano-Sánchez JA. Epidemiología de la cardiopatía isquémica: En Cardiopatía isquémica. Madrid, España: ENE Ediciones; 1999. p.13-71.
Braunwald E. Chronic coronary artery disease. En: Heart Disease, a textbook of cardiovascular medicine. 5a ed. Philadelphia: WB Saunders Company; 1997. p.1316.
Portal de la Secretaría de Salud de México. México: Secretaría de Salud; 2012. Disponible en: http://www.gob.mx/salud
Buxton B, Frazer OH, Westaby S. The Decision-Making Process: en Ischemic Heart Disease, Surgical Management. London: MOSBY; 1999. p.39-57.
World Health Origanization. Health Topics: Cardiovascular diseases. Ginebra, Suiza; World Health Organization: 2014. Disponible en: http://www.who.int/topics/cardiovascular_diseases/en/
Dimmeler S, Mann DL, Zeiher AM. Emerging therapies and strategies in the treatment of heart failure. En: Libby: Braunwald’s Heart Disease. A Textbook of Cardiovascular Medicine.8a ed. Philadelphia: WB Saunders; 2007. p.697-705.
Rosas-Peralta M, Attie F. Enfermedad cardiovascular. Primera causa de muerte en adultos de México y del mundo. Arch Cardiol Mex. 2007;77:91-3.
García-Castillo A, Sánchez-Díaz CJ, Martínez-Sánchez C, Llamas-Esperón G, Cardona E, Barragán R, González-Camid F, Sahagún G, Treviño AJ. Guías clínicas para el manejo del infarto agudo del miocardio con elevación del segmento ST. Arch Cardiol Mex. 2006;76(Supl. 3):S12-S120.
Buda AJ. The role of echocardiography in the evaluation of mechanical complications of acute myocardial infarction. Circulation. 1991;84(Suppl. I):S109-21.
Hasai D, Begar S, Wallentin L, DanchinN, Gitt AK, Boersma et al. A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin. The Euro Heart Survey of Acute Coronary Syndromes. Eur Heart J. 2002;15:1190-201.
Armstrong A, Duncan B, Oliver MF, Julian DG, Donald KW, Fulton et al. Natural history of acute coronary attacks. A community study. Br Heart J. 1972;34:67-80.
Tunstall-Pedoe H, Kuulasmaa K, Mahonen M, Tolonen H, Ruko-Koski E, Amouyel P, for the WHO MONICA Project: Contribution of trends of survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease. Lancet. 1999;353:1547-57.
Grupo Cooperativo RENASICA. Sociedad Mexicana de Cardiología: El Registro Nacional de los Síndromes Isquémicos Coronarios Agudos (RENASICA I). Arch Cardiol Méx. 2002;72(Supl.1):S45-64.
García-Castillo A, Sánchez-Díaz CJ, Martínez BP, Azpiri-López JR, Autrey CA, Martínez-Sánchez C et al. RENASICA II. A Mexican registry of acute coronary syndromes. Arch Cardiol Mex. 2005;75:S18-30.
Manson JE. The primary prevention of myocardial infarction. N Engl J Med. 1992;326(21):1406-16.
Braunwald E, Antman EM. Evidence based coronary care. Ann Intern Med. 1997;126:551-3.
Hunink MG. The recent decline in mortality from coronary heat disease, 1980-1990. The effect of secular trends in risk factors and treatment. JAMA. 1997;277:535-42.
Engler D. Use of vascular endothelial growth factor for therapeutic angiogenesis. Circulation. 1996;94:1496-8.
Selke FW, Jianyi L, Stamler A. Angiogenesis induced by acidic fibroblast growth factor as an alternative method of revascularization for chronic myocardial ischemia. Surgery. 1996;120:182-8.
Ashahara T, Bauters C, Zheng LP. Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. Circulation. 1995;92(Suppl. 2):S365-71.
Folkman J, Shing Y. Angiogenesis. J Biol Chem. 1992;267:1031-4.
Takeshita S, Zheng LP, Brogi E, Kearney M. Therapeutic angiogenesis a single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest. 1994;93(2):662-70.
Banai S, Jaklitsch MT, Schou M, Lazarus DF. Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs. Circulation. 1994;89:2183-9.
Peña-Duque MA. Angiogénesis. Arch Cardiol Mex. 2001;71(Supl.1):S136-8.
Kornowski R, Fuchs S, Leon M, Epstein S. Delivery strategies to achieve therapeutic myocardial angiogenesis. Circulation. 2000;101:454-8.
Henry TD, Annex BH, Azrin MA, Mckendall GR, Willerson JT. Double blind, placebo, controlled trial of recombinant human vascular endothelial growth factor: the VIVA trial. J Am Coll Cardiol. 1999;33(Suppl. A):384A.
Srinivas G, Anversa P, Frishman WH. Cytokines and myocardial regeneration. A novel treatment option for acute myocardial infarction. Cardiol Rev. 2009;17:1-9.
Kornowski R, Fuchs S, Vodovotz Y, Gordon D, Flynn M, Kovesdi I et al. Successful gene transfer in a porcine ischemia model using the biosense guided transendocardial injection catheter. J Am CollCardiol. 1999;33(Suppl. A):355A.
Baumgartner I, Pieczek A, Manor O, Blair R, Kearney M, Walsh K et al. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation. 1998;97(12):1114-23.
Cooley D, Frazer OH, Kadipasaoglu K, Lindenmeir M, Pehlivanoglu S, Wolff J et al. Transmyocardial laser revascularization. Clinical experience with twelve month follow up. J Thorac Cardiovasc Surg. 1996:111:791-9.
Favaloro R, Effler D. History. In Surgical Treatment of coronary arteriosclerosis. Baltimore: Williams and Williams; 1970. p.1-10.
Sabiston D. The coronary circulation. En: SabistonD. Surgery of the chest. 5a ed. Philadelphia: W.B. Saunders; 1990. Vol. II. p.1654-61.
Fernandez-Santander SM. La circulación colateral coronaria en la cardiopatía isquémica. Mexico: Editorial Panamericana; 1997.
Petiti I, Guinovart M, Rig I, Vilallonga J. Introducción histórica y justificación. En: Arterias coronarias. Aspectos anatómo-clínicos. Barcelona: Masson-Salvat; 1993.
Kohmoto T, Argenzino M, Yamamoto N, Vliet K, Gu A, De Rosa C et al. Assesment of transmyocardial perfusion in alligator hearts. Circulation. 1997;95:1585-91.
Tsang J, J-Chiu R. The Phantom of myocardial sinusoids. A historical reappraisal. Ann Thorac Surg. 1995;60:1831-5.
Kirklin J, Barratt-Boyes B. Stenotic arteriosclerotic coronary artery disease. En: Kirklin J, Barratt-Boyes B. Cardiac Surgery. Churchill Livingstone. 1993; Vol. 1. p.286.
Sen PK, Udwadia TE, Kinare SG, Parulkar GB. Transmyocardial acupunture. A new approach to myocardial revascularization. J Thorac Cardiovasc Surg. 1965;50:2:181.
Hammond G, Provan J, Austen GW. Experimental evaluation of myocardial revascularization procedures. Ann Surg. 1966;164;951-8.
Mack MJ. Advances in the treatment of coronary artery disease. Ann Thorac Surg. 2003;76(Suppl.):S2240-5.